Biotech entity

SI-BONE

Company

All 1 tracked stories fall under one category: pharma. AAON is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. SI-BONE appears in 1 tracked Biotech story from March 2, 2026.

Last mentioned: Mar 2, 2026

Entity pulse

Recent coverage · SI-BONE

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about SI-BONE

All 1 tracked stories fall under one category: pharma. AAON is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. SI-BONE appears in 1 tracked Biotech story from March 2, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering SI-BONE. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning SI-BONE 1

Pharma Neutral

Smith & Nephew Sets Ambitious 2028 Targets Following Q4 Results

Smith & Nephew (SNN) has reported its fourth-quarter results and provided a multi-year financial outlook through 2028, signaling a pivot toward sustained growth. The company is leveraging strategic partnerships, including a collaboration with SI-BONE, to expand its footprint in high-growth medtech segments.

2 sources

SI-BONE is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.